Revised Geneva Score Calculator for Pulmonary Embolism
The Revised Geneva Score estimates the pretest probability of pulmonary embolism (PE) using nine standardized clinical criteria - no clinical gestalt required. Select each finding that applies to your patient and the calculator instantly stratifies PE risk as low, intermediate, or high and shows the expected PE prevalence for each category. Use this alongside D-dimer testing and imaging protocols to guide your diagnostic workup.
What is the Revised Geneva Score?
The Revised Geneva Score is a validated clinical prediction rule developed to estimate the pretest probability of pulmonary embolism (PE) in patients presenting with suspected PE. It was introduced by Le Gal and colleagues in 2006 as a fully standardized alternative to the Wells criteria, replacing subjective items like "clinical gestalt" with nine objective, clearly defined clinical variables. Each variable is assigned a fixed point value based on its association with confirmed PE, and the total score places the patient into one of three pretest probability categories: low (0-3), intermediate (4-10), or high (11 or above). The score is widely used in emergency medicine and internal medicine to guide D-dimer testing and CT pulmonary angiography (CTPA).
How the scoring criteria are weighted
The nine variables reflect the major clinical risk factors and signs associated with pulmonary embolism. Unilateral lower extremity edema or deep palpation pain carries the most weight at 4 points, reflecting its direct association with DVT, which is the most common source of PE. Heart rate at or above 95 bpm scores 5 points - the highest of any single variable - because significant tachycardia suggests hemodynamic stress from a possible PE. Heart rate in the 75-94 bpm range scores 3 points. Previous DVT or PE and unilateral lower limb pain each score 3 points, both indicating venous thromboembolism as a likely underlying mechanism. Surgery under general anesthesia or a lower limb fracture within the past month, active malignancy, and hemoptysis each contribute 2 points, reflecting well-established risk factors. Advanced age (over 65) adds 1 point. The maximum possible score is 22 points.
Using the score in clinical practice
The Revised Geneva Score is designed to be used at the point of initial evaluation, before ordering D-dimer or imaging. Patients in the low-probability category (score 0-3) have a PE prevalence of roughly 8-10% and can be effectively ruled out with a negative D-dimer without exposing them to CT radiation or contrast. In the intermediate-probability group (score 4-10), PE prevalence rises to 22-28%: D-dimer testing remains useful, particularly with an age-adjusted threshold for patients over 50 (age x 10 ng/mL instead of the standard 500 ng/mL cutoff). High-probability patients (score 11 or above) have a PE prevalence of 48-74% and should proceed directly to CTPA rather than waiting for D-dimer results, which are almost universally positive in this group and therefore uninformative. Empirical anticoagulation while awaiting imaging may be appropriate in high-probability patients without contraindications.
Revised Geneva Score vs. other PE prediction tools
The most common alternative is the Wells PE score, which uses seven criteria. The key difference is that the Wells score includes a subjective item asking whether PE is the most likely diagnosis ("alternative diagnosis less likely than PE"), which can introduce variability between clinicians. The Revised Geneva Score avoids this entirely, relying on objective data that any provider can apply the same way. Both scores have been shown to have similar diagnostic performance in head-to-head validation studies. A simplified version of the Geneva Score, introduced in 2008, assigns equal weight (1 point each) to each criterion, making it faster to apply but slightly less discriminating. The Revised Geneva Score described here (the weighted version) is the one most commonly referenced in clinical guidelines and research.
Revised Geneva Score: Risk Stratification
| Score | Risk Category | Estimated PE Prevalence | Recommended Next Step |
|---|---|---|---|
| 0-3 | Low probability | 8-10% | D-dimer; if negative, PE excluded |
| 4-10 | Intermediate probability | 22-28% | D-dimer (age-adjusted if >50); if positive, CTPA |
| >=11 | High probability | 48-74% | Direct CTPA; consider empirical anticoagulation |
Score thresholds and estimated PE prevalence from the original validation study (Le Gal et al., Annals of Internal Medicine, 2006).
Frequently asked questions
What is the maximum Revised Geneva Score possible?
The maximum possible score is 22 points, achieved if all nine criteria are present. In practice, most patients score far below this ceiling. The scoring items are: age > 65 (1 point), previous DVT or PE (3), surgery/fracture in past month (2), active malignancy (2), unilateral lower limb pain (3), hemoptysis (2), heart rate >= 95 bpm (5), and unilateral lower extremity edema or palpation pain (4). Note that the two heart rate categories are mutually exclusive, so heart rate can contribute either 0, 3, or 5 points total.
What score separates intermediate from high probability?
A score of 11 or above places the patient in the high-probability category. Scores of 4-10 indicate intermediate probability, and scores of 0-3 indicate low probability. These thresholds come from the original 2006 validation study by Le Gal and colleagues, which defined these bands based on the distribution of confirmed PE prevalence across score ranges in the study cohort.
Does a low Revised Geneva Score rule out pulmonary embolism?
A low score alone does not rule out PE, but a low score combined with a negative D-dimer test effectively excludes PE in most patients without requiring CT imaging. In the validation data, only about 8-10% of patients in the low-probability group have confirmed PE - but that residual risk means D-dimer testing remains essential before discontinuing the workup. Negative D-dimer in a low-probability patient brings the post-test probability below 1-2%, which is generally accepted as safe to discharge.
Can the Revised Geneva Score be used during pregnancy?
The Revised Geneva Score was not specifically validated in pregnant patients and should be used with caution in this population. Pregnancy itself is a well-established risk factor for venous thromboembolism, and many of the physiological changes of pregnancy - including tachycardia and leg edema - can elevate the score independently of PE. Specific PE diagnostic algorithms for pregnant patients, which often prioritize bilateral compression ultrasonography and V/Q scanning over CTPA to minimize fetal radiation exposure, should be consulted.
What is the difference between the Revised Geneva Score and the Simplified Geneva Score?
The Revised Geneva Score (2006) assigns different weights to each criterion based on its strength of association with PE: items score 1, 2, 3, 4, or 5 points. The Simplified Geneva Score (2008) assigns 1 point to each of the same nine criteria, making bedside calculation faster. Studies have shown similar diagnostic performance for both versions, but the weighted Revised Geneva Score remains more widely cited and recommended in major pulmonary embolism guidelines. This calculator uses the weighted 2006 version.
Sources
- Le Gal G, et al. Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Annals of Internal Medicine. 2006;144(3):165-171.
- Klok FA, et al. Simplification of the revised Geneva score for assessing clinical probability of pulmonary embolism. Archives of Internal Medicine. 2008;168(19):2131-2136.